Champions Oncology Posts Record Annual Revenue but Thin Profit Margins Keep Risk Elevated

What happened

Champions Oncology reported FY2026 revenue of $59.4 million, a record, and its fourth straight quarter of positive adjusted EBITDA. However, the full-year adjusted EBITDA of only $1.6 million (2.7% margin) and Q4 at $158,000 highlight razor-thin profitability even as revenue grew modestly. The company continues to invest in radiopharmaceuticals, data platforms, and commercial expansion, which is necessary for future growth but keeps operating cash flow under pressure. Despite the headline revenue record, the data-licensing business remains lumpy and contributed little in the second half, while working capital and cash reserves are tight. Overall, the results confirm a stable but unspectacular trajectory, leaving the stock’s rich valuation vulnerable until higher-margin data or Corellia funding materialize.

Implication

While the FY2026 results demonstrate Champions’ ability to grow revenue and stay EBITDA-positive, the meager profitability and heavy reinvestment leave little margin for error. Unless data-licensing scales meaningfully or Corellia secures external funding to reduce parent-level cash drain, the company faces continued liquidity risk. At ~15x EV/EBITDA on still-modest earnings, the stock offers poor risk-reward, particularly given negative working capital and a history of execution volatility. Investors should wait for proof of durable, high-margin revenue growth before committing capital.

Thesis delta

The record revenue and full-year positive adjusted EBITDA confirm the base-case scenario of stable but unspectacular growth. However, the thin margins and ongoing investment leave the bear case intact. The thesis remains that risk-reward is unfavorable at current levels, and this report does little to shift that assessment.